OSI-027MTORC1/ mTORC2 inhibitor CAS# 936890-98-1 |
- Zanamivir
Catalog No.:BCC4946
CAS No.:139110-80-8
- Oseltamivir acid
Catalog No.:BCC1826
CAS No.:187227-45-8
- Oseltamivir phosphate
Catalog No.:BCC4690
CAS No.:204255-11-8
- Peramivir
Catalog No.:BCC1846
CAS No.:330600-85-6
- Nucleozin
Catalog No.:BCC1811
CAS No.:341001-38-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 936890-98-1 | SDF | Download SDF |
PubChem ID | 44224160 | Appearance | Powder |
Formula | C21H22N6O3 | M.Wt | 406.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 83.33 mg/mL (205.02 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid | ||
SMILES | COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21 | ||
Standard InChIKey | CDNMDRUIGNHEMR-VKAVYKQESA-N | ||
Standard InChI | InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12H,5-8,22H2,1H3,(H,23,24)(H,28,29)/b17-14- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM | ||||||
Targets | mTORC | mTORC1 | mTORC2 | PI3Kγ | DNA-PK | ||
IC50 | 4 nM | 22 nM | 65 nM | 0.42 μM | 1.0 μM |
OSI-027 Dilution Calculator
OSI-027 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4603 mL | 12.3016 mL | 24.6033 mL | 49.2065 mL | 61.5082 mL |
5 mM | 0.4921 mL | 2.4603 mL | 4.9207 mL | 9.8413 mL | 12.3016 mL |
10 mM | 0.246 mL | 1.2302 mL | 2.4603 mL | 4.9207 mL | 6.1508 mL |
50 mM | 0.0492 mL | 0.246 mL | 0.4921 mL | 0.9841 mL | 1.2302 mL |
100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.4921 mL | 0.6151 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
OSI-027 is a potent and selective inhibitor of mTORC1 and mTORC2 with IC50 values of 22nM and 65nM, respectively [1].
OSI-027 is developed as a potent anticancer agent through inhibiting mTORC1 and mTORC2. It shows more than 100-fold selectivity against mTOR over other PI3K-related kinases in biochemical assays. In cellular assays, OSI-027 inhibits the phosphorylation of mTORC1 and mTORC2 substrates including AKT, PRAS40 and S6K1, results in the blockade of downstream signaling. It shows equipotent cellular inhibition of both mTORC1 and mTORC2. It is demonstrated that OSI-027 is more potent in inhibiting cell proliferation and inducing cell death than rapamycin in a lot of tumor cell lines. Besides that, OSI-027 is also found to cause apoptosis via inducing sub-G1 fraction significantly. Furthermore, OSI-027 shows potent antitumor activity in MDA-MB-231 breast cancer xenograft model and human ovarian cancer xenograft models. The antitumor spectrum of OSI-027 is found to be quite broad including breast, colon, lung, prostate, lymphoma, and head and neck cancer [1].
References:
[1] Bhagwat S V, Gokhale P C, Crew A P, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Molecular cancer therapeutics, 2011, 10(8): 1394-1406.
- Forsythoside E
Catalog No.:BCN2782
CAS No.:93675-88-8
- Rengyol
Catalog No.:BCN4481
CAS No.:93675-85-5
- Magnolignan A
Catalog No.:BCN4084
CAS No.:93673-81-5
- VX-809
Catalog No.:BCC3712
CAS No.:936727-05-8
- LCZ696
Catalog No.:BCC5505
CAS No.:936623-90-4
- PCI-32765 (Ibrutinib)
Catalog No.:BCC1266
CAS No.:936563-96-1
- PCI-32765 Racemate
Catalog No.:BCC5124
CAS No.:936563-87-0
- Ajuganipponin A
Catalog No.:BCN3660
CAS No.:936323-13-6
- ACET
Catalog No.:BCC7462
CAS No.:936095-50-0
- TG101348 (SAR302503)
Catalog No.:BCC2190
CAS No.:936091-26-8
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- cAMPS-Sp, triethylammonium salt
Catalog No.:BCC8081
CAS No.:93602-66-5
- Magnolignan C
Catalog No.:BCN4085
CAS No.:93697-42-8
- TC-H 106
Catalog No.:BCC2426
CAS No.:937039-45-7
- Leuconolam
Catalog No.:BCN4482
CAS No.:93710-27-1
- GSK690693
Catalog No.:BCC2483
CAS No.:937174-76-0
- NSC 95397
Catalog No.:BCC7109
CAS No.:93718-83-3
- ARRY-380
Catalog No.:BCC3726
CAS No.:937265-83-3
- SB1317
Catalog No.:BCC1925
CAS No.:937270-47-8
- Pacritinib (SB1518)
Catalog No.:BCC4558
CAS No.:937272-79-2
- Magnaldehyde D
Catalog No.:BCN4070
CAS No.:93753-33-4
- GRP (human)
Catalog No.:BCC5810
CAS No.:93755-85-2
- Jangomolide
Catalog No.:BCN4483
CAS No.:93767-25-0
- Neogambogic acid
Catalog No.:BCN2321
CAS No.:93772-31-7
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.[Pubmed:27002938]
Br J Cancer. 2016 Apr 12;114(8):889-96.
BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. A first-in-human trial evaluating tolerability, pharmacokinetics and pharmacodynamics of the dual TORC1/TORC2 inhibitor OSI-027 was conducted. METHODS: Dose escalation was pursued for three schedules of administration (three consecutive days per week (S1), once a week (S2) and daily dosing (S3)), until dose-limiting toxicities (DLT) were identified. Expansion cohorts with paired tumour biopsies were initiated based on tolerability and pharmacodynamics. RESULTS: One hundred and twenty eight patients with advanced cancer were enrolled. DLT consisted predominantly of fatigue, renal function disturbances and cardiac events. OSI-027 exposure was dose proportional, with Tmax within 4 h and a half-life of approximately 14 h. Expansion cohorts were initiated for S1 and S2, as MTD for S3 was overall considered suboptimal. Target modulation in peripheral blood mononuclear cells were observed from 30 mg, but in tumour biopsies 120 mg QD were needed, which was a non-tolerable dose due to renal toxicity. No RECIST responses were recorded, with stable disease >6 months in six (5%) patients. CONCLUSIONS: OSI-027 inhibits mTORC1/2 in patients with advanced tumour s in a dose-dependent manner but doses above the tolerable levels in S1 and S3 are required for a sustained biological effect in tumour biopsies.
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.[Pubmed:21673091]
Mol Cancer Ther. 2011 Aug;10(8):1394-406.
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, metabolism, proliferation, and survival. Rapamycin and its analogues partially inhibit mTOR through allosteric binding to mTORC1, but not mTORC2, and have shown clinical utility in certain cancers. Here, we report the preclinical characterization of OSI-027, a selective and potent dual inhibitor of mTORC1 and mTORC2 with biochemical IC(50) values of 22 nmol/L and 65 nmol/L, respectively. OSI-027 shows more than 100-fold selectivity for mTOR relative to PI3Kalpha, PI3Kbeta, PI3Kgamma, and DNA-PK. OSI-027 inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo. OSI-027 and OXA-01 (close analogue of OSI-027) potently inhibit proliferation of several rapamycin-sensitive and -insensitive nonengineered and engineered cancer cell lines and also, induce cell death in tumor cell lines with activated PI3K-AKT signaling. OSI-027 shows concentration-dependent pharmacodynamic effects on phosphorylation of 4E-BP1 and AKT in tumor tissue with resulting tumor growth inhibition. OSI-027 shows robust antitumor activity in several different human xenograft models representing various histologies. Furthermore, in COLO 205 and GEO colon cancer xenograft models, OSI-027 shows superior efficacy compared with rapamycin. Our results further support the important role of mTOR as a driver of tumor growth and establish OSI-027 as a potent anticancer agent. OSI-027 is currently in phase I clinical trials in cancer patients.
The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.[Pubmed:26284306]
DNA Cell Biol. 2015 Oct;34(10):610-7.
In the present study, we investigated the potential activity of OSI-027, a potent and selective mammalian target of rapamycin (mTOR) complex 1/2 (mTORC1/2) dual inhibitor, against pancreatic cancer cells both in vitro and in vivo. We demonstrated that OSI-027 inhibited survival and growth of both primary and transformed (PANC-1 and MIA PaCa-2 lines) human pancreatic cancer cells. Meanwhile, OSI-027 induced caspase-dependent apoptotic death of the pancreatic cancer cells. On the other hand, caspase inhibitors alleviated cytotoxicity by OSI-027. At the molecular level, OSI-027 treatment blocked mTORC1 and mTORC2 activation simultaneously, without affecting ERK-mitogen-activated protein kinase activation. Importantly, OSI-027 activated cytoprotective autophagy in the above cancer cells. Whereas pharmacological blockage of autophagy or siRNA knockdown of Beclin-1 significantly enhanced the OSI-027-induced activity against pancreatic cancer cells. Specifically, a relatively low dose of OSI-027 sensitized gemcitabine-induced pancreatic cancer cell death in vitro. Further, administration of OSI-027 or together with gemcitabine dramatically inhibited PANC-1 xenograft growth in severe combined immunodeficiency mice, leading to significant mice survival improvement. In summary, the preclinical results of this study suggest that targeting mTORC1/2 synchronously by OSI-027 could be further investigated as a valuable treatment for pancreatic cancer.
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.[Pubmed:26213847]
Oncotarget. 2015 Sep 22;6(28):26230-41.
Despite its relative rarity, pancreatic ductal adenocarcinoma (PDAC) accounts for a large percentage of cancer deaths. In this study, we investigated the in vitro efficacy of OSI-027, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2, to treat PDAC cell lines alone, and in combination with gemcitabine (GEM). Similarly, we tested the efficacy of these two compounds in a xenograft mouse model of PDAC. OSI-027 significantly arrested cell cycle in G0/G1 phase, inhibited the proliferation of Panc-1, BxPC-3, and CFPAC-1 cells, and downregulated mTORC1, mTORC2, phospho-Akt, phospho-p70S6K, phospho-4E-BP1, cyclin D1, and cyclin-dependent kinase 4 (CDK4) in these cells. Moreover, OSI-027 also downregulated multidrug resistance (MDR)-1, which has been implicated in chemotherapy resistance in PDAC cells and enhanced apoptosis induced by GEM in the three PDAC cell lines. When combined, OSI-027 with GEM showed synergistic cytotoxic effects both in vitro and in vivo. This is the first evidence of the efficacy of OSI-027 in PDAC and may provide the groundwork for a new clinical PDAC therapy.